Billion To One
We are ONE team,
working towards ONE goal to
ONE molecule at a time.
One in a
There are three billion letters, three billion nucleotides that make up our genome. Our proprietary technology has the ability to detect and quantify disease at single base-pair resolution. Our name speaks to this unique technology, and we are focused on applying it to various disease states to help more patients.Mission, Vision, Values
At the Forefront of
Our proprietary Quantitative Counting Templates, or QCTs™, power our ability to detect and measure tiny and sparse disease-related DNA fragments, or molecules, at the single base-pair level. Several common and severe recessive conditions screened for prenatally can be caused by single-base pair alterations.
Our QCT technology enables quantifying these tiny variations using cell-free DNA. We believe this quantification will open the door to exponential improvements in prenatal screening, liquid biopsy, and beyond.
Moving Prenatal Screening and Liquid Biopsy Forward
We assess fetal risk for recessive conditions and aneuploidies from maternal blood.
UNITY Screen™ includes a carrier screen as well as a single-gene (for recessive conditions) and aneuploidy NIPT and only requires a maternal blood draw at 10+ weeks to assess fetal risk. No paternal sample needed.
We are currently open to research collaborations for our liquid biopsy tests.
Northstar Select™ and Northstar Response™ are therapy selection and therapy response monitoring tests, respectively, available for research only.
Coupling Careers with Great Culture
“BillionToOne’s leadership values growth of the company’s employees and equality among peers.”
“I love BillionToOne’s culture, everyone is so welcoming and always open to lend a helping hand.”
“We have a very strong culture of cross-departmental teamwork. Everyone here cares about making an impact!”
“I love being able to introduce the latest and greatest technology to Women’s Health providers that will improve their knowledge on each pregnancy and give babies the best shot at healthy beginnings!”
Coupling Careers with Great Culture
What unites the our team and drives us forward is one goal of making molecular testing more accurate, efficient, and accessible to all. This special group of bright and talented people is improving healthcare. If this appeals to you, consider joining us.
Leading with Passion and Purpose
Co-founders Oguzhan Atay, Ph.D., and David Tsao, Ph.D., and our team of engineers, scientists, and industry experts care deeply about every sample that comes into our lab.
News & MediaView All
BillionToOne appoints Dr. Gary Palmer as Chief Medical Officer, Oncology; Launches Northstar Select™ and Northstar Response™ Liquid Biopsy Assays for Commercial Use
BillionToOne Announces $48.5M Additional Capital Raise and $35M Upsized Term Loan Facility, Demonstrating Investor and Lender Confidence in the Company’s Rapid Growth
BillionToOne Announces New Clinical Outcomes Data Showing High Sensitivity of UNITY Screen™ to Detect Pregnancies at Risk for Recessive Conditions
BillionToOne Appoints Tom Lynch, JD, as General Counsel & Chief Compliance Officer
CA Superior Court Halts CDPH’s Exclusivity of Trisomy Screening Through the CA PNS Program
BillionToOne Launches Novel Fetal Antigen NIPT as Part of UNITY Screen
BillionToOne Ranked a Top Healthcare Technology Company of 2022
BillionToOne launches oncology liquid biopsy products for research use & announces clinical research collaboration with UCSD
BillionToOne Closes $125M Series C Funding with Premier Global Investors
BillionToOne CEO Oguzhan Atay, PhD, named in Top 25 CEOs in Biotech of 2022 by the Healthcare Technology Report